U.S. FDA declines to approve AstraZeneca (US.AZN) treatment for chronic nasal condition - 14 martie 2022: Diferență între versiuni

<p style="text-align: justify;"><br/></p><p style="text-align: justify;">AstraZeneca Plc said on Monday the U.S. drug regulator declined to approve its asthma medicine, Fasenra, for treatment of chronic rhinosinusitis with nasal polyps, a condition characterised by benign growths that cause pain and stuffiness.An approval would have challenged Sanofi's Dupixent and Novartis's Xolair, the two biologic respiratory drugs that have so far won approval to treat chronic rhinosinusitis with nasal polyposis.</p><p style="text-align: justify;"><br/></p><p style="text-align: justify;">[https://finance.yahoo.com/news/1-u-fda-declines-approve-075047188.html https://finance.yahoo.com/news/1-u-fda-declines-approve-075047188.html]<br/></p><p style="text-align: justify;"><br/></p>